STAA logo

STAAR SURGICAL CO

STAANASDAQ
πŸ† #2041 by market capEarnings Aug 12US Equity
$25.10β–² $0.16 (+0.64%)
Live
1hβ–² 0.8%
24hβ–² 0.6%
7dβ–² 9.9%
14dβ–² 5.1%
30dβ–Ό 9.6%
1yβ–Ό 8.3%
🏦Market Cap
$1.25B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+4.0%
Slowing
πŸ“ŠGross Margin
76.9%
High
πŸ’΅FCF Margin
0.6%
Thin
βš–οΈP/S Ratio
4.2x
Fair
Otter Score
54
Weak

Trading Snapshot

Day Range
$24.85 – $25.29
52-Week Range
$15.59 – $35.87
Volume
$2.93B
Avg Volume
$3.03B
Shares Outstanding
49.8M
Next Earnings
Oct 15, 2026

Fundamentals Snapshot

Annual Revenue
$239M
Last Q Revenue
$94M
P/E Ratio
β€”
P/S Ratio
4.2x
EPS (TTM)
$-0.43
Dividend Yield
β€”

Why Investors Own STAA

  • βœ“High-growth profile β€” revenue up +50.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 43% gross margin and 25% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$239Mβ–² +52.3% YoY
Gross Margin (TTM)
42.7%β–Ό βˆ’0.5% YoY
Operating Income (TTM)
$62Mβ–² +52.3% YoY
Free Cash Flow (TTM)
$60Mβ–² +52.3% YoY

About STAAR SURGICAL CO

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
54/100

Analyst Ratings

β“˜
Consensus
Buy
18 analysts
Strong Buy3
Buy5
Hold9
Sell1
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

πŸš€
BenzingaΒ·7d ago

STAAR Surgical Appoints Warren Foust As President And CEO, Effective August 4; Names Deborah Andrews EVP And CFO

Deborah Andrews appointed Executive Vice President and Chief Financial OfficerSTAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of

πŸ›°οΈ
BenzingaΒ·8d ago

Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target

Wedbush analyst Michael Piccolo reiterates Staar Surgical (NASDAQ:STAA) with a Outperform and maintains $40 price target.

SeekingAlphaΒ·25d ago

STAAR Surgical's Punishment For Opacity Is Just

STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance. Read more on STAA stock here.

BenzingaΒ·26d ago

Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions

STAAR Surgical expects preliminary Q2 2026 net sales to top $90 million, driven by strong Americas growth and an inventory rebound in China.

BenzingaΒ·26d ago

Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.

BenzingaΒ·26d ago

Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket

Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.